Daniel D. Von Hoff, M.D., F.A.C.P.

Dr. Von Hoff is currently Physician-in-Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for U.S. Oncology Network and Scottsdale Healthcare’s Clinical Research Institute. He holds an appointment as Professor of Medicine at the Mayo Clinic in Scottsdale, Arizona.

Dr. Von Hoff and his colleagues were involved in the beginning of the development of many of the anti-neoplastic agents including  mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib and others. Dr. Von Hoff has published more than 620 papers, 137 book chapters and over 1050 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care. Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board, serving from 2004-2010.

Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past Board Member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme). Dr. Von Hoff is the Founder and Editor Emeritus of Investigational New DrugsThe Journal of New Anticancer Agents, and Editor-in-Chief of Molecular Cancer Therapeutics. He is a Co-Founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop.